RARE
Ultragenyx Pharmaceutical Inc. · Healthcare · Biotechnology
Momentum inputs (comparable managers):
holder breadth -5.3% ·
share flow -7.7% ·
net new positions -5.6%
· formula
Broad distribution: falling shares and fewer holders
All ownership figures: tracked 13F managers only, common-stock positions, reporting period Q2 2025
| Quarter | Holders | Δ | Shares | Reported value | New | Exits |
|---|---|---|---|---|---|---|
| Q3 2026 | 2 | 0 | 477.97K | $7.18M | +1 | −1 |
| Q2 2026 | 97 | -6 | 59.88M | $1.99B | +8 | −14 |
| Q1 2026 | 106 | +4 | 55.54M | $1.16B | +10 | −7 |
| Q4 2025 | 102 | 0 | 62.50M | $1.44B | +1 | n/a |
| Q3 2025 | 19 | -1 | 45.29M | $1.36B | n/a | −2 |
| Q2 2025 | 18 | -1 | 33.50M | $1.22B | n/a | −1 |
| Q1 2025 | 16 | 0 | 17.22M | $623.52M | n/a | n/a |
| Q4 2024 | 16 | +1 | 16.41M | $690.18M | +1 | n/a |
| Q3 2024 | 14 | +2 | 15.84M | $879.45M | +2 | n/a |
| Q2 2024 | 12 | n/a | 15.75M | $647.24M | n/a | n/a |
| # | Manager | Shares | Δ shares | Value | Their weight | Held | ||
|---|---|---|---|---|---|---|---|---|
| 1 | The Vanguard Group ✦ (passive) | 10.21M | n/a | $371.36M | 0.0% | n/c | 1 | SEC ↗ ×5 |
| 2 | BlackRock ✦ (passive) | 6.26M | n/a | $227.47M | 0.0% | n/c | 1 | SEC ↗ ×17 |
| 3 | T. Rowe Price ✦ | 2.89M | -10.3% | $104.95M | 0.0% | ▼ Trim | 5 | SEC ↗ ×2 |
| 4 | Fidelity (FMR) ✦ | 2.60M | n/a | $94.70M | 0.0% | n/c | 1 | SEC ↗ ×5 |
| 5 | State Street Global Advisors ✦ (passive) | 2.57M | -1.8% | $93.53M | 0.0% | ▼ Trim | 3 | SEC ↗ |
| 6 | Wellington Management ✦ | 1.87M | -23.6% | $68.06M | 0.0% | ▼ Trim | 5 | SEC ↗ ×6 |
| 7 | Geode Capital Management ✦ (passive) | 1.71M | +4.0% | $62.29M | 0.0% | ▲ Add | 5 | SEC ↗ ×2 |
| 8 | Adage Capital Partners ✦ | 1.53M | -28.8% | $55.61M | 0.1% | ▼ Trim | 5 | SEC ↗ |
| 9 | Norges Bank ✦ (passive) | 983.64K | 0.0% | $35.77M | 0.0% | Held | 5 | SEC ↗ |
| 10 | Two Sigma Investments ✦ | 576.90K | -8.9% | $20.98M | 0.0% | ▼ Trim | 5 | SEC ↗ |
| 11 | D. E. Shaw & Co. ✦ | 540.80K | -2.8% | $19.66M | 0.0% | ▼ Trim | 5 | SEC ↗ ×2 |
| 12 | Point72 Asset Management ✦ | 515.97K | -47.1% | $18.76M | 0.0% | ▼ Trim | 5 | SEC ↗ |
| 13 | Millennium Management ✦ | 486.34K | -31.7% | $17.68M | 0.0% | ▼ Trim | 5 | SEC ↗ |
| 14 | AQR Capital Management ✦ | 252.33K | +174.1% | $9.17M | 0.0% | ▲ Add | 5 | SEC ↗ ×4 |
| 15 | Renaissance Technologies ✦ | 208.30K | -30.5% | $7.57M | 0.0% | ▼ Trim | 4 | SEC ↗ |
| 16 | Fisher Asset Management ✦ | 185.76K | -10.6% | $6.75M | 0.0% | ▼ Trim | 3 | SEC ↗ |
| 17 | Marshall Wace ✦ | 65.87K | -80.3% | $2.40M | 0.0% | ▼ Trim | 5 | SEC ↗ |
| 18 | Citadel Advisors ✦ | 37.63K | -85.3% | $1.37M | 0.0% | ▼ Trim | 5 | SEC ↗ |
“Their weight” = the position's share of that manager's reported 13F equity value: the conviction measure. ✦ = curated manager.
New buyers
| No new tracked buyers this quarter. |
Exited
| Duquesne Family Office | $3.09M | was 0.1% |
Full-market context: across ALL 13F filers (SEC structured data, Q1 2026): 293 holders, 97.86M shares, $1.96B reported. This is a different, older period than the tracked-universe figures above and the two are never mixed.
What else this security's tracked holders most often hold: shared-ownership counts, not fundamental relationships.
Open-market purchases (P)
No open-market insider purchases in our coverage window.
Open-market sales (S)
Officer · 7.07K sh · $107,898
Officer · 1.28K sh · $17,410
Officer · 161 sh · $2,252
Awards, exercises and tax withholding are never counted as buys or sales here. Methodology